References
- Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol. 2010;105:43–9.
- Xu D, Yang H, Lai CC, Li P, Zhang X, Yang XO, et al. Clinical analysis of systemic lupus erythematous with gastrointestinal manifestations. Lupus. 2010;19:866–9.
- Chund HH, Tan BE, The CL, Lian TY. Major gastrointestinal manifestations in lupus patients in Asia: lupus enteritis, intestinal pseudo-obstruction, and protein-losing gastroenteropathy. Lupus. 2010;19:1404–13.
- Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic erythematosus. Rheumatology. 1999:38:917–32.
- Yamashita H, Muto G, Hachiya R, Sugiyama H, Takahashi Y, Kenko H, et al. A case of Sjögren’s syndrome complicated by protein-losing gastroenteropathy with unprecedented pulmonary interstitial lesions. Mod Rhuematol. 2014;24:877–9.
- Hsieh TY, Lan JL, Chen DY. Primary Sjögren syndrome with protein-losing gastroenteropathy: report of two cases. J Formos Med Assoc. 2002;101:519–22.
- Nasu Y, Miyata K, Uno A, Kawashima A, Kondo M, Akamizu T, et al. Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome. Case Rep Gastroenterol. 2011;5:372–7.
- Mok MY, Lau CS. Protein losing enteropathy and primary Sjögren's syndrome. Clin Exp Rheumatol. 1997:15:705.
- Uraoka Y, Tanigawa T, Watanabe K, Machida H, Okazaki H, Yamagami H, et al. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab. Am J Gastroenterol. 2012; 107:1266–8.
- Weiser MM, Andres GA, Brentjens JR, Evans JT, Reichlin M. Systemic lupus erythematosus and intestinal vasculitis. Gastroenterology. 1981;81:570–9.
- Koyama H, Tsuji M. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol. 1983;32:3547–53.
- Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575–97.
- Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent development in molecular action and clinical application. Transplant Proc. 1998;30:1573–9.
- Nakayamada S, Fujimoto T, Nonomura A, Saito K, Nakamura S, Tanaka Y. Usefulness of initial histological features for stratifying Sjögren's syndrome responders to mizoribine therapy. Rheumatology (Oxford). 2009;48:1279–82.
- Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274:87–92.
- Sugiyama T, Koike T, Imaizumi T, Matsumura R, Takabayashi K, Sueishi M, et al. A case of Sjögren's syndrome associated with protein-losing enteropathy. Jpn J Clin Immun. 1988;11:80–5.
- Inoue R, Horita M, Kurokawa M, Tatsukawa H, Hata M, Matsuda M, et al. A case of protein losing enteropathy associated with Sjögren's syndrome. Kyushu J Rheumatol. 1996;15:151–5.
- Ushiyama A, Teraoka H, Shiba T, Saito T, Nagata J, Koike J, et al. Protein-losing gastroenteropathy associated with Sjögren's syndrome-case report and review of the Japanese literature. Nihon Shokakibyo Gakkai Zasshi. 2004;101:1314–19.
- Nagashima T, Hoshino M, Shimoji S, Morino N, Kamiura T, Okazaki H, et al. Protein-losing gastroenteropathy associated Sjögren's syndrome: a characteristic oriental variant. Rhumatol Int. 2009;29:817–20.